Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.
about
Orthotopic Heart Transplantation and Mechanical Circulatory Support in Cancer Survivors: Challenges and OutcomesUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Suivi après le traitement du cancer du sein: Guide pratique des soins aux survivantes à l’intention des médecins de familleFollow-up after treatment for breast cancer: Practical guide to survivorship care for family physiciansAggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy.Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy.Characterization and reversal of Doxorubicin-mediated biphasic activation of ERK and persistent excitability in sensory neurons of Aplysia californica.Impairments that influence physical function among survivors of childhood cancerAnticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance.Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature ReviewPharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.Cardiotoxicity of anthracycline therapy: current perspectivesDoxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death.MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat.Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes.Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology.Survivorship.Anthracycline-Induced Cardiomyopathy in Adults.Heart failure and chemotherapeutic agents.Renal toxicity of anticancer agents targeting HER2 and EGFR.High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.Current insights into LMNA cardiomyopathies: Existing models and missing LINCsThe importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.Sarco"MiR" friend or foe: a perspective on the mechanisms of doxorubicin-induced cardiomyopathy.Late mortality among 5-year survivors of early onset cancer: a population-based register study.Development of a Pediatric Cardiac Mechanical Support Program.Mitochondrial ROS-induced ERK1/2 activation and HSF2-mediated AT1 R upregulation are required for doxorubicin-induced cardiotoxicity.Doxorubicin-induced nitrosative stress is mitigated by vitamin C via the modulation of nitric oxide synthases.Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer.Embryonic stem cell-derived cardiomyocytes for the treatment of doxorubicin-induced cardiomyopathy.Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice.
P2860
Q26785414-F9971666-CD9F-4339-A9A4-2C8729C194DDQ27027354-AB14CB10-26C0-4CE2-8370-C4CF85E80A95Q28078524-C6780233-5A62-4248-A899-E50E579AABA6Q28080263-27E1731B-5089-408E-9863-7509627D538FQ33432624-94B216E6-DAB0-47FB-A513-01D5365F92DEQ33853732-D77DEDBB-4055-45A8-8384-6ED4D44129E2Q33866915-523547A1-5279-45C4-8770-A2B6C8852A87Q35082766-B3411E9F-C390-4E88-9F19-CEF8BB3C6437Q35189961-AB35C25E-433A-4092-84C7-E104B4B7A2AAQ35888110-7258CA5D-9BE8-4335-9BD1-FBCCBBC2E77FQ36828315-5247B967-CDEA-4A63-AFE8-E5CBD04D74F5Q36845348-3A2B88C6-008F-4133-8AAE-D3E8C42ACBE4Q37603290-B7CA2674-FC7B-49F7-8E90-AE16D7D8264CQ37641769-FB62A206-B3FD-449C-92E2-29ABBA9E0334Q37704467-3D910FE8-C80E-4FB2-9104-3E80D0FDA66CQ38262595-3D71FAB5-1AD8-48F0-834A-AF66B1B66705Q38306995-7799C566-B106-4086-9A13-17B722C0C327Q38542462-FE10A807-56A3-4C83-B833-C866ACBB7671Q38559133-CA5DD576-86FB-45D6-BFC4-7E79FE59C7F7Q38581146-4AD7312D-4597-4E20-B095-150398EF4CDEQ38868285-622C614C-4F3E-42C7-9140-4FE20A0B23B9Q38888350-B13982E3-BCC1-4831-8E95-B2B68DBF9CD7Q39104972-8713590E-466E-4CD4-94CA-C97D4C77B6F2Q39231153-8439B740-CD3C-415F-B0E2-437A6520F4E5Q41983421-64FC0ADF-1599-49CA-8D34-3E38DA758BC4Q42202408-B23A5706-037D-443C-A107-224BCE81B9EFQ46184882-0E140C21-F18D-4111-A89E-6200E88B5520Q46403967-6758CA24-C0E7-4F57-8DB9-F7D3B1CC7B23Q46431015-F4A9F9E7-9A7C-4E21-8A61-F53CB7413659Q47299200-69D38A03-CC19-4D2A-A1CE-8FDA94FDC6B0Q48245077-BC8EB948-0588-40E5-A2B2-AE5D1913B080Q48505210-EBD7A0D3-1DD8-4D55-A998-4E429D1ED537Q49353792-222DFAA6-ED2F-42A5-9C52-D0FECA403D9BQ51093490-847B3AD4-8E09-4F79-A3E3-B5A6E626DC05Q54979863-82984E1A-50D8-4D39-867C-D1E5E56774A4
P2860
Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anthracycline-induced cardioto ...... ogy, diagnosis, and treatment.
@en
type
label
Anthracycline-induced cardioto ...... ogy, diagnosis, and treatment.
@en
prefLabel
Anthracycline-induced cardioto ...... ogy, diagnosis, and treatment.
@en
P2860
P1476
Anthracycline-induced cardioto ...... ogy, diagnosis, and treatment.
@en
P2093
Shashi Raj
Vivian I Franco
P2860
P2888
P356
10.1007/S11936-014-0315-4
P577
2014-06-01T00:00:00Z